All data are based on the daily closing price as of November 13, 2024
h

Hanall Biopharma

009420.KO
28.89 USD
-2.77
-8.75%

Overview

Last close
28.89 usd
Market cap
1.47B usd
52 week high
36.13 usd
52 week low
14.95 usd
Target price
33.67 usd

Valuation

P/E
N/A
Forward P/E
N/A
Price/Sales
15.7506
Price/Book Value
13.2802
Enterprise Value
1.59B usd
EV/Revenue
17.0799
EV/EBITDA
245.2146

Key financials

Revenue TTM
93.11M usd
Gross Profit TTM
44.19M usd
EBITDA TTM
-2.97M usd
Earnings per Share
N/A usd
Dividend
N/A usd
Total assets
212.91B usd
Net debt
N/A usd

About

Hanall Biopharma Co., Ltd., a pharmaceutical company, manufactures and sells pharmaceutical products in South Korea and internationally. The company offers prescription drugs and over-the-counter products for the treatment of diarrhea, prostatic hyperplasia, androgenetic alopecia, chronic renal failure, hypoparathyroidism, vitamin D-resistant rickets, osteomalacia, osteoporosis, prostate cancer, toxic liver disease, chronic hepatitis, liver cirrhosis, male pattern baldness, functional dyspepsia, diabetes, bacterial infections, peripheral vascular disorders, hypertension, chronic heart failure, skin diseases, hypoproteinemia, diabetic polyneuritis, ulcers, high blood pressure, arthritis, endocrine disorders, spasms, insomnia, muscle pain, hypoproteinemia, gastroesophageal reflux disease, allergic rhinitis, conjunctivitis, dermatitis, chronic urticaria, cholesterol cholelithiasis, gastritis, neurological diseases, erectile dysfunction, hyperphosphatemia, urinary tract infection, spastic paralysis, fungal infections, dysmenorrhea, hypercholesterolemia, constipation, abdominal distension, abdominal fermentation in the intestines, neuralgia, capillary weakness, post-phlebitis syndrome, irritable bowel syndrome, spastic colon, and hemorrhoids, as well as vitamin D, vitamin B1, vitamin B12, and calcium deficiency. It develops products in the fields of ophthalmology, immunology, oncology, and neurology, such as HL192 for Parkinson's disease; HL036 for dry eye disease; HL161 for myasthenia gravis, thyroid eye disease, warm autoimmune hemolytic anemia, neuromyelitis optica, immune thrombocytopenia, chronic inflammatory demyelinating polyneuropathy, and graves' disease; and HL187 and HL186 for immuno-oncology. The company was founded in 1973 and is headquartered in Daejeon, South Korea.
  • Symbol
    009420.KO
  • Exchange
    KO
  • Isin
    KR7009420001
  • Country
    South Korea
  • Sector
    Healthcare
  • Industry
    Drug Manufacturers - Specialty & Generic
  • CEO
    Sean Jeong
  • Headquarter
    Daejeon
  • Web site
    https://www.hanall.co.kr
Jakota Newsletter

Stay ahead in the JAKOTA stock markets with our roundup of vital insights

Icon scroll to top